SCHEMBL2736809

SCHEMBL2736809

CCCCn1cc(-c2ccc(CC)cc2)cc(C(=O)NCCCN2CCOCC2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.52
CNR2 P34972 1/20 0.52
KDM5B Q9UGL1 1/20 0.51
MAPT P10636 1/20 0.51
ALDH1A1 P00352 3/20 0.49
LMNA P02545 2/20 0.48
TSHR P16473 2/20 0.47
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TYRO3 Q06418 1/20 0.46
MERTK Q12866 1/20 0.46
GAS6 Q14393 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736855 0.92 SMN1; SMN2 (0.55) CNR1CNR2ALDH1A1LMNATSHR
SCHEMBL2736815 0.91 CNR2 (0.64) CNR1CNR2MAPTALDH1A1LMNA
SCHEMBL2736895 0.89 HRH3 (0.51) CNR1CNR2MAPTALDH1A1LMNA
SCHEMBL2736798 0.89 CNR1 (0.51) CNR1CNR2MAPTALDH1A1LMNA
SCHEMBL2736880 0.89 CD274 (0.56) CNR1CNR2ALDH1A1LMNATSHR
SCHEMBL2736841 0.86 KDM4E (0.56) CNR1CNR2ALDH1A1LMNATSHR
SCHEMBL2736851 0.86 TSHR (0.48) CNR1CNR2MAPTALDH1A1LMNA
SCHEMBL2736865 0.86 CHEK1 (0.47) CNR1CNR2ALDH1A1LMNATSHR
SCHEMBL2736846 0.84 SMYD2 (0.54) MAPTALDH1A1LMNATSHRKDM4E
SCHEMBL2736818 0.84 TDP1 (0.54) CNR1CNR2ALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR1 2/4885CNR2 1/4885KDM5B 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.